Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Chiron Corp.

(CHIR)

Business: Biopharmaceuticals

Morgan Stanley's Hecht raised his 12-month price target to $93 from $83, after the Emeryville, Calif., company reported better than expected second quarter results. EPS of 2

Read the full 327 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE